Navigation Links
Laresse Dermal Filler Research Presented at Anti-Aging World,Congress

SAN LUIS OBISPO, Calif.--(BUSINESS WIRE)--Mar 22, 2007 - FzioMed, Inc. announced today that a review of the company's research on novel, synthetic dermal fillers is being presented at the Anti-Aging Medical World Congress (AAMWC) in Monte Carlo March 22-24, 2007.

In 2006, FzioMed launched Laresse Dermal Filler, the first ultra-smooth, non-permanent, synthetic filler created from the company's patented polymer science. Laresse represents a completely new class of filler for the correction of wrinkles and lines caused by sun exposure, aging and other factors.

After extensive characterization of cross-linked hyaluronic acid (HA) fillers, FzioMed designed Laresse from biocompatible polymers to have key gel properties that offer significant advantages over common fillers being used today. For example, Laresse is stable without chemical cross-linking, completely free of both bacterial and animal by-products, and smoother and easier to inject than HA fillers.

Richard Berg, Ph.D., FzioMed's Chief Scientific Officer, will present "Novel Synthetic Dermal Fillers" at AAMWC on March 24th. His talk will describe the rheological properties of commercialized cross-linked HA fillers and includes data demonstrating the broader versatility and advantages of FzioMed's polymer technology for formulating a family of improved dermal fillers, including Laresse.

"This presentation highlights FzioMed's approach of applying science to the rapidly evolving field of soft tissue augmentation," said John Krelle, FzioMed President & Chief Executive Officer.

About Laresse

Laresse Dermal Filler is an ultra-smooth, non-permanent, non-HA gel composed of pure, absorbable medical polymers. Laresse is the first non-permanent filler without many of the drawbacks of HA and collagen fillers. No other filler offers the same features as Laresse: non-permanent wrinkle correction, non-animal and non-bacterial compone
'"/>




Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. NIEHS Researchers Identify Enzyme Critical in DNA Replication
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. Researchers Discover Method for Identifying How Cancer Evades the Immune System
7. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
8. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
9. President Bush Ignores Americas Plea for Support of Stem Cell Research
10. Researchers Discover Gene For Rare Skin Disorder
11. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
Post Your Comments:
Breaking Medicine Technology:AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 1Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 2Crosstalk between critical cell signaling pathways holds clues to tumor invasion and metastasis 62132 3Tailor made HIV AIDS treatment closer to reality 62127 1Tailor made HIV AIDS treatment closer to reality 62127 2Its not just dirt 21 10899 1Its not just dirt 21 10899 2
Breaking Medicine News(10 mins):Health News:McGraw-Hill Education's Online Resources Ease Learning at Home During H1N1 Outbreak 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 3Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 4Health News:Pharmacists Encourage Consumers to Practice Safe Medication Storage and Disposal 2Health News:Pharmacists Encourage Consumers to Practice Safe Medication Storage and Disposal 3Health News:Aurora Health Care and ECRS Complete 112 Location Retail Automation Project 2Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 2Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 3Health News:Consumer Watchdog Releases Coercive Lobbying E-Mail to Employees of United Health Group, Calls It 'Political Harassment' of Workers 4